162 related articles for article (PubMed ID: 26033699)
1. [Renal cysts - A novel complication of crizotinib treatment for lung cancer].
CsToth I; Meert AP; Sculier JP; Berghmans T
Rev Mal Respir; 2015 Nov; 32(9):956-8. PubMed ID: 26033699
[TBL] [Abstract][Full Text] [Related]
2. Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib.
Taima K; Tanaka H; Tanaka Y; Itoga M; Takanashi S; Tasaka S
Intern Med; 2017 Sep; 56(17):2321-2324. PubMed ID: 28794366
[TBL] [Abstract][Full Text] [Related]
3. Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics.
Halpenny DF; McEvoy S; Li A; Hayan S; Capanu M; Zheng J; Riely G; Ginsberg MS
Lung Cancer; 2017 Apr; 106():33-36. PubMed ID: 28285691
[TBL] [Abstract][Full Text] [Related]
4. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
5. Widespread renal polycystosis induced by crizotinib.
Di Girolamo M; Paris I; Carbonetti F; Onesti EC; Socciarelli F; Marchetti P
Tumori; 2015 Jul; 101(4):e128-31. PubMed ID: 25953441
[TBL] [Abstract][Full Text] [Related]
6. Complex renal cysts associated with crizotinib treatment.
Schnell P; Bartlett CH; Solomon BJ; Tassell V; Shaw AT; de Pas T; Lee SH; Lee GK; Tanaka K; Tan W; Tang Y; Wilner KD; Safferman A; Han JY
Cancer Med; 2015 Jun; 4(6):887-96. PubMed ID: 25756473
[TBL] [Abstract][Full Text] [Related]
7. Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report.
Madabhavi I; Patel A; Anand A; Panchal H; Parikh S
Clin Respir J; 2018 Feb; 12(2):806-810. PubMed ID: 27606884
[TBL] [Abstract][Full Text] [Related]
8. Infected complex renal cysts during crizotinib therapy in a patient with non-small cell lung cancer positive for ALK rearrangement.
Yoneshima Y; Okamoto I; Arimura-Omori M; Kimura S; Hidaka-Fujimoto N; Iwama E; Harada T; Takayama K; Nakanishi Y
Invest New Drugs; 2015 Apr; 33(2):510-2. PubMed ID: 25433426
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution.
Cameron LB; Jiang DH; Moodie K; Mitchell C; Solomon B; Parameswaran BK
Cancer Imaging; 2017 Feb; 17(1):7. PubMed ID: 28209203
[TBL] [Abstract][Full Text] [Related]
10. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer.
Lin YT; Wang YF; Yang JC; Yu CJ; Wu SG; Shih JY; Yang PC
J Thorac Oncol; 2014 Nov; 9(11):1720-5. PubMed ID: 25436806
[TBL] [Abstract][Full Text] [Related]
11. Development of complex renal cysts: A complication associated with Crizotinib therapy.
Chen F; Patel NJ; Legout JD; Caserta MP
Clin Imaging; 2020 Sep; 65():15-17. PubMed ID: 32353713
[TBL] [Abstract][Full Text] [Related]
12. Crizotinib and renal insufficiency: a case report and review of the literature.
Martín Martorell P; Huerta Alvaro M; Solís Salguero MA; Insa Molla A
Lung Cancer; 2014 Jun; 84(3):310-3. PubMed ID: 24703892
[TBL] [Abstract][Full Text] [Related]
13. Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma.
Tsukita Y; Fukuhara T; Kobayashi M; Morita M; Suzuki A; Watanabe K; Noguchi T; Kurata Y; Suno M; Maemondo M
Intern Med; 2015; 54(24):3185-8. PubMed ID: 26666609
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib-Associated Renal Cysts in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients: A Single-Center Experience.
Eiamprapaporn P; Mungwatthana N; Twinprai P; Sookprasert A; Chindaprasirt J; Ahooja A; Watthanaudomrot S; Sirithanaphol W
Urol Int; 2020; 104(3-4):269-272. PubMed ID: 31480046
[TBL] [Abstract][Full Text] [Related]
15. Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation.
Chun SG; Iyengar P; Gerber DE; Hogan RN; Timmerman RD
J Clin Oncol; 2015 Feb; 33(5):e25-6. PubMed ID: 24616318
[No Abstract] [Full Text] [Related]
16. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment with alectinib after crizotinib-induced interstitial lung disease.
Chino H; Sekine A; Kitamura H; Kato T; Ogura T
Lung Cancer; 2015 Dec; 90(3):610-3. PubMed ID: 26452431
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib-induced esophageal ulceration: a novel adverse event of crizotinib.
Park J; Yoshida K; Kondo C; Shimizu J; Horio Y; Hijioka S; Hida T
Lung Cancer; 2013 Sep; 81(3):495-496. PubMed ID: 23891512
[TBL] [Abstract][Full Text] [Related]
19. Complex renal cysts combined with hemorrhage during crizotinib treatment for ALK-rearranged lung adenocarcinoma.
Yang L; Gu J; Niu X
Cancer Treat Res Commun; 2021; 27():100373. PubMed ID: 33865115
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.
Rosoux A; Pauwels P; Duplaquet F; D'Haene N; Weynand B; Delos M; Menon R; Heukamp LC; Thunnissen E; Ocak S
Lung Cancer; 2016 Aug; 98():118-121. PubMed ID: 27393517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
